about
2,8-bis(trifluoromethyl)quinoline analogs show improved anti-Zika virus activity, compared to mefloquineThe clinically approved antiviral drug sofosbuvir inhibits Zika virus replicationN-(2-(arylmethylimino)ethyl)-7-chloroquinolin-4-amine derivatives, synthesized by thermal and ultrasonic means, are endowed with anti-Zika virus activityGenome sequencing reveals Zika virus diversity and spread in the AmericasZika virus evolution and spread in the Americas.Brazil nuts intake improves lipid profile, oxidative stress and microvascular function in obese adolescents: a randomized controlled trialHepadnavirus detected in bile and liver samples from domestic pigs of commercial abattoirs.Genotypic Characterization of Herpes Simplex Virus Type 1 Isolates in Immunocompromised Patients in Rio de Janeiro, BrazilCynomolgus monkeys are successfully and persistently infected with hepatitis E virus genotype 3 (HEV-3) after long-term immunosuppressive therapy.Changes in cellular proliferation and plasma products are associated with liver failure.Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae.Acute liver failure in an immunocompetent patient.Corrigendum: The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication.Knowledge about viral hepatitis among participants of Gay Pride Event in Brazil.An observational clinical case of Zika virus-associated neurological disease is associated with primary IgG response and enhanced TNF levels.Capturing diverse microbial sequence with comprehensive and scalable probe designBeyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replicationEmergence of the East-Central-South-African genotype of Chikungunya virus in Brazil and the city of Rio de Janeiro may have occurred years before surveillance detection
P50
Q28114553-567DF8C4-6232-4022-81EF-D2086E2CA7DCQ28595139-C3A05783-44F7-4A42-8A5C-05C35E2FBDDAQ28595161-F7C8A0A2-1F19-45C4-BEE6-64345FA1585FQ28803990-329EAFD4-8A53-4476-BDC2-C466D34D0FFAQ30145571-48851E60-5B08-4D38-883C-918A870D60E7Q34629586-3DC8E7CE-3277-4867-9492-C8473133A37EQ35510026-18BC7938-A193-4343-B58A-0C0F955C3316Q35788664-BE7E83A4-DA52-458C-A5F8-C30AE6491AA2Q36318218-A6623B97-C55F-4840-8847-35C0D93644D3Q37421478-031E1042-5A5D-49B8-8847-8D5771270F4AQ38156553-48460C18-AE81-4777-90CC-182B5499035DQ39343787-06501091-8373-45B9-8940-9C2A18374656Q40047394-3657B13B-5272-4876-9D79-A541870CD78DQ45718797-88CA834E-AD27-475E-BD79-A2EB13A0D936Q54208977-C1EDDF54-21BA-4AE7-992E-3C301B3A11F3Q56762946-0E371061-DEB2-4ECF-BDF9-306E41B2AF26Q59245634-8D0F5174-6243-40D1-8474-BB946DD9D0FEQ62485445-312DFE6D-409F-4BCC-9328-DA2CE941B3BE
P50
name
Yasmine Rangel Vieira
@ast
Yasmine Rangel Vieira
@en
Yasmine Rangel Vieira
@nl
type
label
Yasmine Rangel Vieira
@ast
Yasmine Rangel Vieira
@en
Yasmine Rangel Vieira
@nl
prefLabel
Yasmine Rangel Vieira
@ast
Yasmine Rangel Vieira
@en
Yasmine Rangel Vieira
@nl